Regeneron Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGRegeneron Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 36), showing significant lag compared to the market leaders. Earnings contraction of 7% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $623.38 | +8.48% | ABOVE |
| 50 SMA | $653.79 | +3.43% | ABOVE |
| 100 SMA | $708.81 | -4.60% | BELOW |
| 150 SMA | $725.20 | -6.75% | BELOW |
| 200 SMA | $700.72 | -3.50% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is REGN in an uptrend right now?
REGN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is REGN overbought or oversold?
REGN's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is REGN outperforming the market?
REGN has a Relative Strength (RS) Rating of 36 out of 99. REGN is currently lagging the broader market.
Where is REGN in its 52-week range?
REGN is trading at $676.23, which is 82% of its 52-week high ($821.11) and 49% above its 52-week low ($537.45).
How volatile is REGN?
REGN has a Beta of 0.45 and 52-week volatility of 33%. It's less volatile than the S&P 500 - generally more stable.